重组人血小板生成素与白介素-11治疗急性白血病化疗后血小板减少96例的疗效对比观察

目的：评价重组人血小板生成素（ rhTPO）治疗白血病化疗后血小板（ PLT）减少症的疗效和安全性。方法96例白血病患者随机分为治疗组（重组人血小板生成素，rhTPO）与对照组（重组人白介素-11，rhIL-11），分别皮下注射，观察外周血小板的变化。结果治疗组血小板的最低值和恢复的最高值显著高于对照组；治疗组的PLT ＜50×10^9 L-1的持续时间、恢复到70×^109 L-1和125×10^9 L-1所需要的时间，显著低于对照组所需时间；治疗组不良反应少且较轻微。结论重组人血小板生成素（ rhTPO）治疗急性白血病化疗后的血小板减少症疗效显著且安全性好。

Comparison the Efficacy in 96 Cases of rhTPO with rhIL-11 in the Treatment of Chemotherapy In-d uced Thrombocytop enia in Patients with Leukemia

Objce tive To evaluate the efficacy and safety of recombinant human thrombopoietin （ rhTPO） compared with recombinant human interleukin 11（rhIL-11）in the treatment of chemotherapy induced thrombocytopenia in patients with leukemia.Methods Ninety -six patients with leukemia were divided into trial and control groups random-ly.Patients in trial group were given rhTPO subcutaneously and patients in control group were given rhIL -11 subcutane-ously.The peripheral platelet count was observed consecutively.Results The mean minimal and maxima platelet count in the trial group was significantly higher than the control group.The time of platelet count less than 50 ×109 L-1 and needed to achieve a level to 70 ×10^9 L-1 and 125 ×10^9 L-1 in the trial group were significantly shorter than in the con-trol group.Slight adverse reaction was observed in the trial group.Conc lusions rhTPO is effective and safety in treat-ment of acute leukemia chemotherapy induced thrombocytopenia.